Market Overview

Ebola Stocks Continue Higher

Related BCRX
6 Movers To Keep An Eye On Next Week
FedBizOpps Reporting Biocryst Received $12,133,606 For BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies

With over 700 already dead, the worst Ebola outbreak in history is pressuring the demand for development of new drugs to fight the Ebola virus.

On Friday, The U.S. Food and Drug Administration said the agency stands ready to work with companies to develop drugs for patients "in dire need of treatment."

Some of the companies that are likely to benefit include Tekmira Pharmaceuticals (NASDAQ: TKMR), Nano Vircides (NASDAQ: NNVC) and BioCryst Pharamceuticals (NASDAQ: BCRX).

Shares of all three companies were trading higher on the open, with TKMR up nearly 15 percent at $16.50.

Posted-In: EbolaNews Global Movers


Related Articles (BCRX + NNVC)

Get Benzinga's Newsletters